Successful Use of Intragastric Balloon Therapy as a Bridge to Heart Transplantation

被引:0
作者
Neej J. Patel
Victoria Gómez
D. Eric Steidley
Lori Roust
Juan Carlos Leoni Moreno
Neena S. Abraham
Rahul Pannala
机构
[1] Mayo Clinic,Division of Gastroenterology and Hepatology
[2] Mayo Clinic,Division of Gastroenterology and Hepatology
[3] Mayo Clinic,Division of Cardiology
[4] Mayo Clinic,Division of Endocrinology
[5] Mayo Clinic,Division of Cardiology
来源
Obesity Surgery | 2020年 / 30卷
关键词
Intragastric balloon; Endoscopic bariatric therapy; Heart transplantation;
D O I
暂无
中图分类号
学科分类号
摘要
Obesity is an important limiting factor for heart transplantation (HT) in patients with congestive heart failure (CHF). Achieving substantial weight loss is challenging in this population due to activity limitations and fluid retention. Endoscopic bariatric therapies (EBTs) including intragastric balloons (IGB) are effective primary weight loss therapies. IGBs have also been successfully utilized as a bridge therapy prior to liver transplantation and, in one case report, prior to HT. Potential advantages of IGBs in this population include low bleeding risk and less invasiveness as compared to other EBTs and surgery. We report the successful use of IGB as a bridge therapy in two patients with class II obesity and end-stage CHF requiring left ventricular assist devices (LVAD), anticoagulation, antiplatelet, and inotrope therapy.
引用
收藏
页码:3610 / 3614
页数:4
相关论文
共 58 条
  • [1] Mehra MR(2016)The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update J Heart Lung Transplant 35 1-23
  • [2] Canter CE(2010)The effect of body mass index on survival following heart transplantation: do outcomes support consensus guidelines? Ann Surg 251 144-152
  • [3] Hannan MM(2019)Endoscopic bariatric therapies: Intragastric balloons, tissue apposition, and aspiration therapy Curr Treat Options Gastroenterol 17 187-201
  • [4] Semigran MJ(2016)Delayed gastric emptying as a proposed mechanism of action during intragastric balloon therapy: results of a prospective study Obesity 24 1849-1853
  • [5] Uber PA(2015)ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies Gastrointest Endosc 82 425-38.e5
  • [6] Baran DA(2016)Single fluid-filled intragastric balloon safe and effective for inducing weight loss in a real-world population Clin Gastroenterol Hepatol 16 1073-1080.e1
  • [7] Danziger-Isakov L(2017)Intragastric balloon for management of morbid obesity in a candidate for heart transplantation J Heart Lung Transplant 36 820-821
  • [8] Kirklin JK(2015)ASGE position statement on endoscopic bariatric therapies in clinical practice Gastrointest Endosc 82 767-772
  • [9] Kirk R(2016)Intragastric balloon as a novel modality for weight loss in patients with cirrhosis and morbid obesity awaiting liver transplantation Indian J Gastroenterol 35 113-116
  • [10] Kushwaha SS(undefined)undefined undefined undefined undefined-undefined